In a new study, researchers compared cardiovascular outcomes among adults with diabetes who initiated first-line treatment with either metformin or SGLT-2i.
Comparison of SGLT-2i and Metformin on Patients
In the new study, 8,613 patients treated with SGLT-2i were matched to 17,226 patients treated with metformin.‘Sodium glucose co-transport inhibitors may be considered as first-line treatment for patients with type 2 diabetes and cardiovascular disease or who are at increased risk for cardiovascular events.’
Read More..
The authors found that patients receiving SGLT-2i showed a similar risk for myocardial infarction, stroke, and all-cause mortality, and a lower risk for hospitalization for heart failure compared with patients who received metformin.Read More..
The risk for adverse events was similar except for an increased risk for genital infections compared with those receiving metformin.
“Our results suggest that SGLT-2i may be considered as first-line treatment for patients with T2D and cardiovascular disease or who are at increased risk for cardiovascular events,” said lead author HoJin Shin, BPharm, PhD, of the Division of Pharmacoepidemiology and Pharmacoeconomics.
“However, more evidence from randomized clinical trials or observational studies will help us to identify patients who would benefit most from using SGLT-2i as first-line type 2 diabetes treatment.”
Advertisement
SGLT2 Inhibitors Provide Kidney, Heart Protection
Sodium-glucose cotransporter 2(SGLT2) inhibitors intake was linked to a lower risk of developing cardiovascular disease and kidney failure among patients with type 1 diabetes.
Sodium-glucose cotransporter 2(SGLT2) inhibitors intake was linked to a lower risk of developing cardiovascular disease and kidney failure among patients with type 1 diabetes.
